在代谢功能障碍相关的脂肪性肝病中,两步临床护理途径的预后性表现

Terry Cheuk-Fung Yip1, Hye Won Lee2, Huapeng Lin3

  • 1Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China; State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.

Journal of hepatology
|January 25, 2025
PubMed
概括

使用纤维化-4指数 (FIB-4) 和肝硬度测量 (LSM) 的两步方法有效地识别了与代谢功能障碍相关的脂肪性肝病 (MASLD) 患者的肝脏相关事件风险不同. 这种非侵入性方法有助于风险分层,以更好地管理患者.